Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
- Initial Results From Clinical Trials Expected by End of This Year - SEATTLE and SAN FRANCISCO, June 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today announced...
SEATTLE, June 7 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX), which is changing its name to Poniard Pharmaceuticals, Inc. effective June 16, 2006, today announced that Jerry...
Leading GPO Experiences Substantial Growth Since January 2005 Launch SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Onmark, a leading national group purchasing organization (GPO) for...
SEATTLE, May 31 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX), which is changing its name to Poniard Pharmaceuticals, Inc. effective June 16, 2006, today announced treatment of the...
SEATTLE, May 15 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX), which is changing its name to Poniard Pharmaceuticals, Inc. effective June 16, 2006, today reported unaudited results...
Corporate and Clinical Update Conference Call Scheduled for 1:00 p.m. EDT Today SEATTLE, May 10 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that it has treated the...
SEATTLE, May 8 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at two upcoming conferences in May: Rodman...
SEATTLE, May 3 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that it will hold a conference call to provide a corporate update, including an update on the clinical...
Nicholas J. Simon Joins Board of Directors SEATTLE, April 27 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that it has completed its previously announced $65 million...
SEATTLE, April 25 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that it has received all shareholder approvals required to proceed with its previously announced $65...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
